UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K/A
(AMENDMENT
NO. 1)
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date of
Report (Date of earliest event reported): September 3,
2009
NEOSTEM,
INC.
(Exact
Name of Registrant as Specified in Charter)
|
Delaware
(State
or Other Jurisdiction of Incorporation)
|
0-10909
(Commission
File
Number)
|
22-2343568
(IRS
Employer Identification
No.)
|
420 Lexington Avenue, Suite
450, New York, New York 10170
(Address
of Principal Executive Offices)(Zip Code)
(212)
584-4180
Registrant's
Telephone Number
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
|
o
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
|
o
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
o
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
|
o
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
EXPLANATORY NOTE:
This
Current Report on Form 8-K/A is being filed by NeoStem, Inc., a Delaware
corporation (“NeoStem” or the “Company”), to amend and restate in its entirety,
as set forth below, Item 1.01 of the Company’s Current Report on Form 8-K
(the “Original Form 8-K”), dated September 3, 2009 and filed with the
Securities and Exchange Commission on September 9, 2009. All of
the other Items and disclosure in the Original Form 8-K are unchanged by
this amendment.
|
Item
1.01.
|
Entry
into a Material Definitive
Agreement.
|
NeoStem
has entered into an agreement for the lease of space from Rivertech Associates
II, LLC, c/o The Abbey Group (the “Landlord”) at 840 Memorial Drive, Cambridge,
Massachusetts with a lease term effective September 1, 2009 through August 31,
2012 (the “Lease”). The space will be used for general office,
research and development, and laboratory space (inclusive of an adult stem cell
collection center). The base rent under the Lease is $283,850 for the
first year, $356,840 for the second year and $369,005 for the third
year. In addition, the Company will be responsible for certain costs
and charges specified in the Lease, including utilities, operating expenses and
real estate taxes. The security deposit is $84,141, which may be
reduced to $56,094 if Company has not defaulted in the performance of its
obligations under the lease prior to the second lease year. To help
defray the cost of the Lease, Company will share with Alnara Pharmaceutical Inc.
(“AP”) certain of the leased premises and AP will pay the Company $5,000 a
month.
SIGNATURE
Pursuant to the requirements of the
Securities Exchange Act of 1934, NeoStem has duly caused this Report to be
signed on its behalf by the undersigned hereunto duly authorized.
|
NEOSTEM,
INC.
|
||||
|
By:
|
/s/
Catherine M. Vaczy
|
|||
|
Name:
|
Catherine
M. Vaczy
|
|||
|
Title:
|
Vice
President and General Counsel
|
|||
Date:
September 9, 2009